Kane Biotech Inc. (TSXV:KNE)
0.0450
0.00 (0.00%)
Jan 20, 2026, 2:01 PM EST
Kane Biotech Revenue
Kane Biotech had revenue of 8.50K CAD in the quarter ending September 30, 2025, a decrease of -99.34%. This brings the company's revenue in the last twelve months to 574.87K, down -71.44% year-over-year. In the year 2024, Kane Biotech had annual revenue of 2.08M with 1,296.75% growth.
Revenue (ttm)
574.87K
Revenue Growth
-71.44%
P/S Ratio
14.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.08M | 1.93M | 1,296.75% |
| Dec 31, 2023 | 148.98K | -7.75K | -4.95% |
| Dec 31, 2022 | 156.73K | -1.45M | -90.25% |
| Dec 31, 2021 | 1.61M | 266.20K | 19.84% |
| Dec 31, 2020 | 1.34M | -351.95K | -20.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.78B |
| dentalcorp Holdings | 1.66B |
| Trulieve Cannabis | 1.66B |
| Green Thumb Industries | 1.61B |
| Extendicare | 1.59B |
| WELL Health Technologies | 1.25B |
| Sienna Senior Living | 967.05M |
| DRI Healthcare Trust | 270.19M |
Kane Biotech News
- 4 weeks ago - Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company - GlobeNewsWire
- 4 weeks ago - Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting - GlobeNewsWire
- 5 weeks ago - Kane Biotech Wins Approval For Revyve Antimicrobial Wound Gel Spray In Canada - Nasdaq
- 7 weeks ago - Kane Biotech Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Kane Biotech Announces $800K Private Placement To Advance Wound Care Portfolio - Nasdaq
- 7 weeks ago - Kane Biotech Announces New Private Placement Offering - GlobeNewsWire
- 2 months ago - Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences - GlobeNewsWire
- 4 months ago - Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser - GlobeNewsWire